The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Apolipoprotein E element 4 association with dementia in a population-based study: The Framingham Study
Abstract
Apolipoprotein E type 4 allele (apoE epsilon4) is associated with Alzheimer's disease (AD) in the late-onset familial form and in sporadic cases, but the age-associated risk in a randomly sampled elderly population is not established. We examined the association of apoE epsilon4 with AD and other dementias (mainly multi-infarct or dementia following stroke) in 1,030 persons aged 71 to 100 years in the population-based Framingham Study cohort. Kaplan-Meier survival analysis revealed that 55% of the apoE epsilon4/epsilon4 homozygotes developed AD by age 80, whereas 27% of apoE epsilon3/epsilon4 heterozygotes developed AD by age 85, and 9% of those without a 4 allele developed AD by age 85 years. In comparison with persons without a 4 allele, the risk ration for AD was 3.7 (95% CI = 1.9 to 7.5) for apoE epsilon3/epsilon4 heterozygotes and 30.1 (95% CI = 10.7 to 84.4) for apoE epsilon4 homozygotes. ApoE epsilon2 (2/2, 2/3, or 2/4 genotypes) was associated with an absence of AD. One-half (n=21) of the 43 AD patients were either homozygous or heterozygous for apoE epsilon4. We found evidence for an association of apoE epsilon4 with other dementia, primarily multi-infarct dementia and stroke. The risk ratio was 2.3 (95% CI = 0.9 to 6.1) for non-AD dementias among persons with apoE epsilon3/epsilon4. Although the apoE epsilon4 allele is a potent risk factor for AD and may be associated with other forms of dementia, most apoE epsilon4 carriers do not develop dementia, and about one-ha…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Being homozygous or heterozygous for the ⑀4 allele increases the risk of LOAD 4-fold and lowers the age of onset of the disease (4,5).”
From Molecular Basis for Increased Risk for Late-onset Alzheimer Disease Due to the Naturally Occurring L28P Mutation in Apolipoprotein E4 (2014) · cites this paper as [5]
Citations
Cites
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Epidemiological approaches to heart disease: the Framingham study
Dawber, T. R., Meadors, G. F., & Moore, F. E. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.3.279 · Cited by 2,148
Dawber, T. R. (1980) · Harvard University Press eBooks · doi:10.4159/harvard.9780674492097 · Cited by 1,965
AN INVESTIGATION OF CORONARY HEART DISEASE IN FAMILIES
Kannel, W. B., Feinleib, M., McNAMARA, P. M., Garrison, R. J., & Castelli, W. P. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112813 · Cited by 1,639
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Cyclic guanosine monophosphate as a mediator of vasodilation.
Murad, F. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112536 · Cited by 799
Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage.
(1991) · Europe PMC (PubMed Central) · Cited by 758
Neurosurgical horizons in Parkinson's disease
Goetz, C. G., Long, M. R. D., Penn, R. D., & Bakay, R. A. E. (1993) · Neurology · doi:10.1212/wnl.43.1_part_1.1 · Cited by 405
Megadose corticosteroids in multiple sclerosis
Kupersmith, M. J., Kaufman, D., Paty, D. W., Ebers, G. C., McFarland, H., Johnson, K., Reingold, S. C., & Whitaker, J. N. (1994) · Neurology · doi:10.1212/wnl.44.1.1 · Cited by 386
Ross, D. A., Dollimore, N., Smith, P. G., Kirkwood, B. R., Arthur, P., Morris, S. S., Addy, H. A., Binka, F., Arthur, P., Gyapong, J. O., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)91879-q · Cited by 384
Research works printed but not linked: 12
- Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein element 4 allele in patients with Alzheimer's disease. Ann Neurol 1993;34:752-754.
- Kuusisto J, Koivisto K, Kervinen K, et al. Association of apolipoprotein E phenotype with late-onset Alzheimer's disease: population-based study. BMJ 1994;309:636-638.
- Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study. Neurology 1993;43:515-519.
- Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990;31:545-548.
- Utterman G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987;113:433-440.
- 10.1016/0140-6736(93)91879-Q · DOI
- 10.1016/0140-6736(93)91878-P · DOI
- Myers RH Schaefer EJ Wilson PWF et al. Apolipoprotein E allele 4 is associated with dementia in the Framingham Study. In: Iqbal K Mortimer J Winblad B Wisniewski H eds. Research advances in Alzheimer's disease and related disorders. John Wiley & Sons Ltd. Chichester England: 1995:63-70.
- van Duijn CM, de Knijff P, Wehnert A, et al. The apolipoprotein E2 allele is associated with an increased risk of earlyonset Alzheimer's disease and a reduced survival. Ann Neurol 1995;37:605-610.
- St. Clair D, Norrman J, Perry R, Yates C, Wilcock G, Brookes A. Apolipoprotein E element 4 allele frequency in patients with Lewy body dementia, Alzheimer's disease and age-matched controls. Neurosci Lett 1994;176:45-46.
- McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
- 10.1212/WNL.45.1.1 · DOI
Cited by
Sorted by citations
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237
Self-citationEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. P. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,271
Clinical Neurology and Epidemiology of the Major Neurodegenerative DiseasesPreprint
Erkkinen, M. G., Kim, M., & Geschwind, M. D. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,231
Dementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806
Metadata
- Authors
- Myers, R. H., Schaefer, E. J., Wilson, P. W. F., D'Agostino, R., Ordovas, J. M., Espino, A., Au, R., White, R. F., Knoefel, J. E., Cobb, J. L., McNulty, K. A., Beiser, A., & Wolf, P. A.
- Affiliations
- Boston University (US)
- Venue
- Neurology
- Published
- 1996-03
- Volume
- 46
- Issue
- 3
- Pages
- 673-677
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1972509050
- Cited by
- 346
- References
- 30
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 1 · 2023: 4 · 2022: 10 · 2021: 12 · 2020: 5 · 2019: 10 · 2018: 8 · 2017: 6 · 2016: 6 · 2015: 13 · 2014: 11 · 2013: 16 · 2012: 24
- FWCI
- 16.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01hc038038-022)
- National Institute on Aging (2-R01-AG08122-06, R01AG008122)
- National Heart, Lung, and Blood Institute (N01-HC-38038)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- APOE ε4, Alzheimer's disease, dementia, multi-infarct dementia, stroke, genetic risk factors, APOE genotype, Framingham Heart Study, older adults, positive predictive value, genetic screening
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Base Sequence, Dementia, Female, Humans, Longitudinal Studies, Male, Middle Aged, Molecular Sequence Data, Sensitivity and Specificity, Cohort Studies, Molecular Probes, Incidence, Odds Ratio, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
